|
1
|
Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer‐Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Ghia P, Wierda WG. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2021. [DOI: 10.1002/hon.32_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. S. L Tam
- Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne Haematology and Disease Group, Melbourne VIC Australia
| | - J. N Allan
- Weill Cornell Medicine, Hematology/Oncology New York USA
| | - T Siddiqi
- City of Hope National Medical Center Hematology Duarte USA
| | - T. J Kipps
- UCSD Moores Cancer Center Chronic Lymphocytic Leukemia San Diego USA
| | - R Jacobs
- Levine Cancer Institute Hematology and Medical Oncology Charlotte USA
| | - S Opat
- Monash University, Clinical Haematology Clayton VIC Australia
| | - P. M Barr
- Wilmot Cancer Institute University of Rochester Medical Center Hematology/Oncology Rochester USA
| | - A Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Haematology Milan Italy
| | - L Trentin
- Hematology and Clinical Immunology Unit Department of Medicine University of Padova, Hematology Padova Italy
| | - R Bannerji
- Rutgers Cancer Institute of New Jersey Hematology/Oncology New Brunswick USA
| | - S Jackson
- Middlemore Hospital, Haematology Auckland New Zealand
| | - B Kuss
- Flinders University and Medical Centre Haemotology and Molecular Genetics, Bedford Park SA Australia
| | - C Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - E Szafer‐Glusman
- Pharmacyclics LLC, an AbbVie Company, Translational Medicine Sunnyvale USA
| | - K Russell
- Pharmacyclics LLC, an AbbVie Company, Clinical Program Development Sunnyvale USA
| | - C Zhou
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - J Ninomoto
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - P Ghia
- ivision of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Experimental Oncology Milan Italy
| | - W. G Wierda
- University of Texas MD Anderson Cancer Center Leukemia Houston USA
| |
Collapse
|
|
2
|
Kipps T, Fraser G, Coutre S, Brown J, Barrientos J, Barr P, Byrd J, O'Brien S, Dilhuydy M, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan A, Mahler M, Salman M, Cheng M, Londhe A, Ninomoto J, Howes A, James D, Hallek M. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_99] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T.J. Kipps
- Department of Medicine; UC San Diego Moores Cancer Center; La Jolla USA
| | - G. Fraser
- Department of Oncology, Juravinski Cancer Centre; McMaster University; Hamilton Canada
| | - S.E. Coutre
- Division of Hematology, Stanford Cancer Center; Stanford University School of Medicine; Stanford USA
| | - J.R. Brown
- Division of Hematologic Malignancies; Dana-Farber Cancer Institute; Boston USA
| | - J.C. Barrientos
- Division of Hematology and Medical Oncology, Department of Medicine, CLL Research and Treatment Program; Northwell Health Cancer Institute; Hempstead USA
| | - P.M. Barr
- Department of Medicine, Hematology/Oncology, James P. Wilmot Cancer Center; University of Rochester; Rochester USA
| | - J.C. Byrd
- Division of Hematology, Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center; Columbus USA
| | - S.M. O'Brien
- Chao Family Comprehensive Cancer Center; University of California; Irvine, Orange USA
| | - M. Dilhuydy
- Department of Hematology; CHU Hopitauz de Bordeaux; Pessac France
| | - P. Hillmen
- Department of Haematology; The Leeds Teaching Hospitals, St. James Institute of Oncology; Leeds UK
| | - U. Jaeger
- Division of Hematology and Hemostaseology; Medical University of Vienna; Wien Austria
| | - C. Moreno
- Hematology Department; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - P. Cramer
- Department of Internal Medicine and Center of Integrated Onology Cologne Bonn; University of Cologne; Cologne Germany
| | - S. Stilgenbauer
- Department of Internal Medicine, Division of Hematology; University of Ulm; Ulm Germany
| | - A.A. Chanan-Khan
- Department of Hematology/Oncology; Mayo Clinic Cancer Center; Jacksonville USA
| | - M. Mahler
- Global Medical Affairs Lead; Janssen Research & Development, LLC; Raritan USA
| | - M. Salman
- Janssen Research & Development, LLC; Raritan USA
| | - M. Cheng
- Biometrics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - A. Londhe
- Biostatistics; Janssen Research & Development, LLC; Raritan USA
| | - J. Ninomoto
- Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - A. Howes
- Clinical Leader; Janssen Research & Development; Wycombe UK
| | - D.F. James
- Clinical Research; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - M. Hallek
- Department of Internal Medicine and Center of Integrated Onology Cologne Bonn; University of Cologne; Cologne Germany
| |
Collapse
|
|
3
|
Ghia P, Tam C, Siddiqi T, Stevens D, Flinn I, Russell K, Eckert K, Zhou C, Ninomoto J, James D, Wierda W. AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Ghia
- Division of Molecular Oncology and Department of Onco-Hematology; Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele; Milan Italy
| | - C.S. Tam
- Department of Haematology; Peter MacCallum Cancer Centre and St. Vincent's Hospital; East Melbourne Australia
| | - T. Siddiqi
- Department of Hematology/Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA
| | - D. Stevens
- Medical Oncology/Hematology; Norton Cancer Institute; Louisville USA
| | - I.W. Flinn
- Blood Cancer Research Program; Sarah Cannon Research Institute; Nashville USA
| | - K. Russell
- Clinical Trial Manager; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - K. Eckert
- Biomarkers; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - C. Zhou
- Biometrics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - J. Ninomoto
- Clinical Science; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - D.F. James
- Clinical Research; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston USA
| |
Collapse
|
|
4
|
Tam C, Byrd J, O'Brien S, Coutre S, Barr P, Furman R, Kipps T, Burger J, Stevens D, Sharman J, Ghia P, Flinn I, Zhou C, Ninomoto J, James D, Wierda W. EFFECT OF SINGLE-AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C.S. Tam
- Department of Haematology; Peter MacCallum Cancer Centre and St. Vincent's Hospital; Melbourne Australia
| | - J.C. Byrd
- Division of Hematology, Department of Internal Medicine; The Ohio State University Medical Center; Columbus USA
| | - S. O'Brien
- Chao Family Comprehensive Cancer Center; University of California Irvine; Orange USA
| | - S. Coutre
- Division of Hematology, Stanford Cancer Center; Stanford University School of Medicine; Stanford USA
| | - P.M. Barr
- James P. Wilmot Cancer Center
- Department of Medicine, Hematology/Oncology, Wilmot Cancer Institute; University of Rochester Medical Center; Rochester USA
| | - R.R. Furman
- Division of Hematology and Medical Oncology; Weill Cornell Medical College; New York USA
| | - T.J. Kipps
- Department of Medicine; University of California San Diego, Moores Cancer Center; La Jolla USA
| | - J.A. Burger
- Department of Leukemia; University of Texas, MD Anderson Cancer Center, Houston; Houston USA
| | - D. Stevens
- Medical Oncology/Hematology; Norton Cancer Institute; Louisville USA
| | - J. Sharman
- US Oncology Research; Willamette Valley Cancer Institute & Research Center; Eugene USA
| | - P. Ghia
- Division of Molecular Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele; Milan Italy
| | - I. Flinn
- Blood Cancer Research Program; Sarah Cannon Research Institute; Nashville USA
| | - C. Zhou
- Biometrics, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - J. Ninomoto
- Clinical Science, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - D.F. James
- Clinical Research, Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA
| | - W.G. Wierda
- Department of Leukemia; University of Texas, MD Anderson Cancer Center, Houston; Houston USA
| |
Collapse
|